Company profile
Penumbra, Inc.
NYSE: PEN · Healthcare · Medical - Devices
#130 of 1,422 Healthcare companies by revenue64th-percentile growth
EA Score
83B+FH 89DQ 84GM 63SS 79
v0.1 · 65/100 weight · provisional
↑ market scale, Altman-Z · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$1.5B
Rev growth YoY (TTM)
+17.3%
Net income (FY)
$177.7M
Employees
4,700
as of 2026-08-05
Market cap
$12.8B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4B$1.4B2025
Net income$177.7M$177.7M2025
Operating income$189.2M$189.2M2025
Total assets$1.8B$1.8B2025
Liabilities$398.9M$398.9M2025
Equity$1.4B$1.4B2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY23
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Penumbra, Inc.’s revenue?
Penumbra, Inc. booked $1.4B in FY2025 revenue, growing 17% year over year — faster than most Healthcare companies we track, at a 12.7% net margin.
Peers · Healthcare
Guardian Pharmacy Services, Inc.63CLifeStance Health Group, Inc.65BAddus HomeCare Corporation80B+Halozyme Therapeutics, Inc.85ACONMED Corporation83B+Haemonetics Corporation79B+Neighbors
Alameda →Key facts
CEOAdam Elsesser
SectorHealthcare
IndustryMedical - Devices
HeadquartersAlameda, CA
ExchangeNYSE: PEN
Employees4,700
IPO date2015-09-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.